6YG.F IMMUNOCORE HLDGS ADS/1
- Market cap
- EUR 1.45B
- P/E
- -
- P/B
- 3.97x
- ROE
- -0.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6YG.F undervalued?
Graham numberThe Graham number of IMMUNOCORE HLDGS ADS/1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IMMUNOCORE HLDGS ADS/1 fundamental analysis
No fundamental analysis for IMMUNOCORE HLDGS ADS/1 yet.
IMMUNOCORE HLDGS ADS/1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneo…
Full company profileIMMUNOCORE HLDGS ADS/1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IMMUNOCORE HLDGS ADS/1 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 174M | 249M | 310M | 400M | 433M |
| Gross Profit | 173M | 248M | 307M | 395M | 430M |
| Operating Income | -51.7M | -59.6M | -70.5M | -45.4M | -12.4M |
| EBITDA | -30.1M | -51.6M | -29.9M | -3.67M | 13.1M |
| Net Income | -52.5M | -55.3M | -51.1M | -35.5M | -2.75M |
| EPS | -1.09 | -1.11 | -1.02 | -0.70 | -0.05 |
| Balance Sheet | |||||
| Total Assets | 527M | 597M | 1.01B | 1.07B | 1.13B |
| Total Liabilities | 188M | 228M | 649M | 686M | 710M |
| Shareholders' Equity | 339M | 369M | 361M | 381M | 420M |
| Cash & Short-term Investments | 402M | 443M | 456M | 468M | 512M |
| Cash Flow | |||||
| Operating Cash Flow | -49.2M | 2.94M | 26.1M | -10.7M | 29.7M |
| Capital Expenditure | 2.20M | 5.43M | 5.17M | 4.34M | 6.55M |
| Free Cash Flow | -51.4M | -2.49M | 20.9M | -15.1M | 23.1M |
| Ratios | |||||
| ROE | -15.5% | -15.0% | -14.2% | -9.3% | -0.7% |
| ROA | -10.0% | -9.3% | -5.1% | -3.3% | -0.2% |
| Net Profit Margin | -30.1% | -22.2% | -16.5% | -8.9% | -0.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
IMMUNOCORE HLDGS ADS/1 dividends
IMMUNOCORE HLDGS ADS/1 has not paid dividends in the last 4 fiscal years.
Who owns IMMUNOCORE HLDGS ADS/1
- Insiders 0.07%
- Institutions 98.82%
- Public & others 1.12%
- Shares outstanding 51.5M
- Free float 46.0M
IMMUNOCORE HLDGS ADS/1 company profile
- Company name
- IMMUNOCORE HLDGS ADS/1
- Ticker
- 6YG.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 524
- Fiscal year end
- December
- Address
- 92 Park Drive, Abingdon, United Kingdom, OX14 4RY
- Phone
- 44 12 3543 8600
- Website
- immunocore.com
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
IMMUNOCORE HLDGS ADS/1 management
10- Dr. Bahija Jallal Ph.D.CEO & Executive Director · born 1961
- Mr. Travis Alan Coy M.B.A.CFO, Executive VP & Head of Corporate Development · born 1980
- Dr. Kripa Ram Ph.D.Executive VP & Chief Operating Officer · born 1963
- Mr. John Goll IIISVP, Finance & Chief Accounting Officer
- Ms. Annelise Vuidepot Ph.D.Chief Science and Technology Officer & Milton Park Site Head
- Mr. Sean D. BuckleyVP & Chief Information Officer · born 1983
- Mr. Ryan BakerVice President of Investor Relations
- Ms. Lily Margaret HepworthExecutive VP, General Counsel & Company Secretary · born 1983
- Ms. Elizabeth Varki Jobes Esq., J.D.Chief Compliance Officer · born 1967
- Mr. Sébastien DesprezVice President of Communications